StockNews.AI
LUCD
StockNews.AI
20 days

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

1. Lucid Diagnostics will host a business update call on August 13, 2025. 2. CEO Lishan Aklog and CFO Dennis McGrath will present key updates and Q2 financials. 3. Lucid focuses on diagnostics for GERD patients to prevent esophageal cancer. 4. EsoGuard® is the first commercially available early detection tool for esophageal precancer.

5m saved
Insight
Article

FAQ

Why Bullish?

The upcoming conference call suggests positive operational updates, potentially boosting investor confidence. Historical announcements often lead to temporary price increases for companies announcing positive growth strategies.

How important is it?

The article details a significant business update, which can directly impact short-term stock movements. A well-received financial call typically results in increased stock interest and potential price appreciation.

Why Short Term?

Investor sentiments may rise in the short term surrounding the conference updates. Such events typically influence immediate market reactions.

Related Companies

PAVM
Conference Call and Webcast at 8:30 AM Eastern Time , /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com. About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com. SOURCE Lucid Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News